Dr Kris Jeremy
Profiles

Dr Kris Jeremy

Lecturer in Biomedical Science

School of Biomedical & Healthcare Sciences (Plymouth University Peninsula Schools of Medicine and Dentistry)

Role

Lecturer in Biomedical Science

Qualifications

Background

Royal Air Force
GlaxoSmithKline
IdentiGEN UK

Qualifications
BSc (Hons) Biochemistry - Swansea University
PhD Biomedical Science - UWE, Bristol
Postgraduate Certificate in Teaching and Learning in Higher Education (PGCHE) - UWE, Bristol

Professional membership

Society of Biology (Member)
Chartered Biologist (CBiol)
Higher Education Academy (Fellow)

Teaching interests

Programme Lead
BSc (Hons) Biomedical Science

Module lead

BHCS3004 Specialist Biochemistry and Screening
BHCS3011 Clinical Immunology and Biochemical Screening
BHCS3024 Diet, Exercise and Chronic Disease
BIOM5012 Clinical Biochemistry

Teaching
BHCS1001 Biomedical Investigation and Experimentation
BHCS1002 Human Anatomy and Physiology: Cells to Systems
BHCS1003 Human Metabolism
DIET106    Nutritional Biochemistry
BHCS1005 Human Disease
BHCS1007 Foundations of Healthcare Science Practice and Workplace Learning
BHCS1010 Introduction to Human Nutrition
BHCS2001 Biology of Disease
BHCS2002 Evidence-Based Practice in Biomedical Science
BHCS2005 Clinical Haematology and Biochemistry
BHCS2007 Diagnostic and Clinical Biomedicine
BHCS2010 Evidence Based Practice in Healthcare Science
BHCS2011 Healthcare Life Science Professional
BHCS2015 Healthcare Physiological Science Professional
BHCS2019 Methods in Human Bioscience
BHCS2020 Human Metabolism
DIET211    Diet, Metabolism and Health
BHCS2025 Nutritional Science 2
BHCS3001 Personal Research Project
BHCS3004 Specialist Biochemistry and Screening
BHCS3008 Current Developments in Biomedical Science
BHCS3011 Clinical Immunology and Biochemical Screening
BHCS3022 Contemporary Issues in Human Health
BHCS3024 Diet, Exercise and Chronic Disease
BIOM5002 Contemporary Applications of Cell Biology
BIOM5012 Clinical Biochemistry

Research interests

CD47 signalling in erythrocytes and AML cell lines

CD47 is a five transmembrane cell surface protein of the immunoglobulin (Ig) superfamily, which is heavily glycosylated and expressed by virtually all cells in the body. Ligation of CD47 with a monoclonal antibody (BRIC 126) and a synthetic peptide (4N1K) based on the C terminal binding domain of Thromobospondin-1 (TSP-1) leads to phosphatidylserine (PS) exposure and cell death in erythrocytes. Recent research has shown that CD47 is upregulated on solid tumours and is overexpressed on acute myeloid leukaemia (AML) cell lines. Overexpression of CD47 indicates poor prognosis in AML hence blockade of CD47 has improved cancer therapy. CD47 is also prognostic for breast cancer. 

Recent research (unpublished) has shown measurable amounts of PS exposure and cell death in several AML cell lines in response to BRIC 126. It is hoped that research into this pathway will help to elucidate the underlying molecular mechanisms responsible for CD47 mediated phosphatidylserine exposure in AML cell lines. Several targets within this proposed pathway have already been identified for further study.

Jeremy, K. P., Plummer, Z. E., Head, D. J., Madgett, T. E., Sanders, K. L., Wallington, A., Storry, J. R., Gilsanz, F., Delaunay, J. & Avent, N. D. (2009) 4.1R-deficient human red blood cells have altered phosphatidylserine exposure pathways and are deficient in CD44 and CD47 glycoproteins. Haematologica, 94, 1354-61. 


Jeremy K, Delaunay J, Gilsanz F, Avent N Opposing effects of protein kinase A and C causes differential phosphatidylserine exposure in a CD47 receptor mediated erythrocyte apoptotic pathway (2008) Haematologica 93, S1:188 

Jeremy K, Plummer Z, Head D, Delaunay J, Gilsanz F, Avent N Proteomic and Biochemical Profiling of 4.1R deficient red blood cells (2007) Haematologica; 92, S1:342-343

Reports & invited lectures

25th British Blood Transfusion Society Annual Scientific Meeting, Glasgow SECC, Glasgow, September 13th-15th 2007 - Special Interest Group